News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Pharmaceutical Technology Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody's Ratings has upgraded Teva's corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook. Moody's …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Teva Pharmaceutical Industries reported record quarterly UZEDY sales, with a significant year over year …
Teva Pharmaceutical Industries Limited TEVA reported second-quarter 2026 adjusted earnings of 2 cents per share, which missed the Zacks Consensus Estimate of 8 cents. Adjusted earnings declined 97% year over year due to higher acquisition costs. Adjusted earnings included an impact of a loss …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting second quarter 2026 results, combining a reported net loss of US$576 million with …
In the past week, Teva Pharmaceutical Industries reported Q2 2026 results showing largely flat sales of US$4,142 million year-on-year but shifting from net income of US$282 million to a net loss of US$576 million, driven in part by impairment charges and acquisition-related costs. Despite …
Teva Pharmaceuticals CEO Richard Francis speaks to Bloomberg's Romaine Bostick about the company's positive Q2 earnings, the impending impact of changing Medicare rules on patients, and the new listing on the NYSE. View Comments
This article first appeared on GuruFocus. Revenue: Approximately $4.1 billion, down 1% in U.S. Dollars or 3% in local currency compared to Q2 2025. Net Loss: $576 million. Non-GAAP Gross Margin: 55.4%, an increase of 80 basis points year-over-year. Non-GAAP Operating Margin: 9%, including …
Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents …
Teva stock advances after the pharmaceutical company reports mixed second-quarter earnings but raises its full-year revenue outlook. Continue Reading
Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.14 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 0.8%. EPS of $0.02 for the same period compares to $0.66 a year ago. The reported revenue represents a surprise of +1.43% over …
MONTPELLIER, France, July 29, 2026--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 …
Teva Pharmaceutical Industries Ltd Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over …
For decades, pharmaceutical advertising largely revolved around television commercials urging patients to ask their doctors about branded medication. Increasingly, however, drugmakers are investing in a different kind of marketing campaign—one built around trusted athletes who have publicly discussed their own health struggles. The latest …
Teva can look beyond President Donald Trump’s threat of a tariff on generic drugs. Teva has a pipeline of branded drugs that has caught Wall Street’s attention. Continue Reading
In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA) is predicted by Wall Street analysts to post quarterly earnings of $0.08 per share, reflecting a decline of 87.9% compared to the same period last year. Revenues are forecasted to be $4.1 billion, representing a …
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States